Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities

K Suresh, J Naidoo, CT Lin, S Danoff - Chest, 2018 - Elsevier
Immune checkpoint inhibitors (ICIs) are newer, immunotherapy-based drugs that have been
shown to improve survival in advanced non-small cell lung cancer (NSCLC). Unlike
traditional chemotherapeutic agents, ICIs work by boosting the body's natural tumor killing
response. However, this unique mechanism of action has also led to the recognition of class-
specific side effects. Labeled immune-related adverse events, these toxicities can affect
multiple organ systems including the lungs. Immune-mediated lung injury because of ICI …